Surfing the MASH Tsunami

S4-E40.4 - Challenges in Treating and Assessing Adequately


Listen Later

Send us a text

Along with NASH-TAG, Paris NASH is one of two famously small, science-based and publicly available events every year for the liver community. Given the depth of topics and ideas explored in Paris, the event in its entirety would be nearly impossible to cover in a single conclusive episode. That said, the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) are joined by two presenting KOLs, Scott Friedman and Laurent Castera, for a neatly packaged conversation to capture some of the key dynamics of the meeting. Particularly, the group hone in on developments in the landscape around NITs.

This conversation starts with a question from Louise about whether utilizing CAP would provide added insight in light of what the group has discussed around NITs in the preceding conversations. Laurent responds that CAP is more related to inflammation and steatosis than to fibrosis, and Scott agrees. Laurent suggests that MRI-PDFF would be an ideal test for addressing this issue, but it is not cost-effective for regular practice. Therefore, he uses VCTE measures, including CAP, because the numbers he provides are motivating to patients. Louise asks how activation of stellate cells depends on disease and Scott notes that most stellate cell activation is driven by inflammation, not fat. However, this raises two challenges: whether lipotoxic mediators drive fibrosis directly or act through inflammation and, more broadly, that current clinical tools for measuring fat are quite broad. On this point, Jörn notes that as the liver progresses toward cirrhosis, it loses fat and thus makes  the entire issue more complex. Roger raises the question whether patient compliance and adherence might be affected negatively by uncertainty about the meaning of results. The rest of this conversation centers around Scott’s comment about the complicated impact of using GLP-1s and other incretins to treat obesity will have on Steatotic Liver Disease (SLD) and challenges in treating and assessing adequately. 

This episode and its conversations cover a range of fascinating insights stemming from yet another impactful Paris NASH meeting. If you have questions or comments around Paris NASH, NITs or any other themes addressed, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected].

Stay Safe and Surf On!



...more
View all episodesView all episodes
Download on the App Store

Surfing the MASH TsunamiBy SurfingNASH.com

  • 3.9
  • 3.9
  • 3.9
  • 3.9
  • 3.9

3.9

24 ratings


More shows like Surfing the MASH Tsunami

View all
Freakonomics Radio by Freakonomics Radio + Stitcher

Freakonomics Radio

32,330 Listeners

Planet Money by NPR

Planet Money

30,874 Listeners

Pivot by New York Magazine

Pivot

9,654 Listeners

Diabetes Core Update by American Diabetes Association

Diabetes Core Update

106 Listeners

The School of Greatness by Lewis Howes

The School of Greatness

21,243 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,374 Listeners

The Daily by The New York Times

The Daily

113,041 Listeners

Up First from NPR by NPR

Up First from NPR

57,015 Listeners

The Indicator from Planet Money by NPR

The Indicator from Planet Money

9,580 Listeners

The Peter Attia Drive by Peter Attia, MD

The Peter Attia Drive

8,700 Listeners

All-In with Chamath, Jason, Sacks & Friedberg by All-In Podcast, LLC

All-In with Chamath, Jason, Sacks & Friedberg

10,269 Listeners

Consider This from NPR by NPR

Consider This from NPR

6,455 Listeners

EASL Podcasts by European Association for the Study of the Liver

EASL Podcasts

0 Listeners

Docs Who Lift by Docs Who Lift

Docs Who Lift

418 Listeners

The Headlines by The New York Times

The Headlines

670 Listeners